Pharma BD Deal Intelligence

Roche Holding AG / AC Immune SA

2012 · Licensing/Option · $418M · Terminated

Genentech (Roche) and AC Immune exclusive worldwide license/research collaboration for anti-tau antibodies in Alzheimer's. Undisclosed upfront plus up to CHF 400M (~$418M) in research/dev/commercial milestones. Built on prior crenezumab (anti-amyloid) deal from 2006.

Key facts

• Announced Jun 18, 2012
• Closed Jun 18, 2012
• Deal value $418M
• Deal type Licensing/Option
• Therapeutic area Alzheimer's disease and other neurodegenerative diseases
• Indications Alzheimer's disease and other neurodegenerative diseases
• Key assets Anti-tau antibodies (semorinemab/RG6100)
• Mechanism Anti-tau monoclonal antibody

← Browse all deals  ·  How we score deals